A new Porcine Circovirus vaccine has received full USDA licensure. Circumvent PCV from Intervet, Inc is a Type 2, Killed Baculovirus Vector and is labelled "for use in healthy swine, 3 weeks of age or older as an aid in the prevention of viremia and as an aid in the prevention of virus shedding caused by Porcine Circovirus." 

The vaccine has been shown to reduce mortality substantially and to provide consistently superior growth performance through processing versus non-vaccinates, according to the manufacturer. Circumvent PCV can be used in pigs as early as three weeks of age. For optimal immune response pigs should receive two 2 cc doses given through intramuscular injection three weeks apart, with vaccinations suggested at three and six weeks of age.

Field studies involving Circumvent PCV vaccination at 3 and 6 weeks of age indicate that improved growth metrics in vaccinates versus controls may prove more economically significant for producers than the reduction in mortality. Circumvent PCV contains Microsol Diluvac Forte (MDF) adjuvant, a highly effective dual adjuvant proven safe in millions of vaccinates.

In efficacy studies conducted by Intervet Inc. for licensure, vaccination with Circumvent PCV was shown to prevent PCV2 viremia as well as nasal and fecal shedding in a dual challenge model (PCV2 and PRRS) while PCV2 challenged controls were 100 percent positive.

For more information, contact John Foxx at (302) 934-4366, or john.foxx@Intervet.com

Source: Intervet News Release